Coronavirus company news summary – Eurofins launches reagents for automated extraction of Genomic SARS-CoV-2 RNA – US FDA issues EUA for Impella heart pumps to support Covid-19 patients

5 August 2020 (Last Updated August 5th, 2020 11:05)

Eurofins Technologies has launched reagents for automated isolation of SARS-CoV-2 RNA from viral particles of human respiratory specimens. The magnetic bead based automated method of reagents extracts and isolates virus particles and their respective RNA on several open platforms for real-time RT-PCR analysis using IVD kits.

The US FDA has issued an emergency use authorisation (EUA) for Abiomed's left-sided Impella heart pumps. The heart pump provides left ventricular unloading and support to patients who are suffering from Covid-19 and undergoing extracorporeal membrane oxygenation (ECMO) treatment and develop pulmonary edema or myocarditis.

An updated version of the ‘do-it-yourself’ ventilation unit initially designed by undergraduate engineering students at Rice University and later developed by the Houston manufacturer Stewart & Stevenson Healthcare Technologies has secured EUA from the US FDA. The device, originally developed at Rice University’s Oshman Engineering Design Kitchen (OEDK) by undergraduate students, was called the ApolloBVM.

Sensor solutions supplier Ams has provided sensor technology to Midge Medical, a German medical technology startup, to develop a rapid genetic and blood testing at a lower cost. Midge Medical is focused on developing a pocket-sized Covid-19 genetic test with results that can be read-out using a smartphone in just 15 minutes.